Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2020 – HER2+
SABCS 2020 – HER2+
Utilization of Circulating Tumor Cells to Help Guide Treatment with HER2 Therapy
SABCS 2020 – HER2+
Contemporaneous monitoring of HER2 status with circulating tumor cells may help to identify patients who may benefit from modifying the treatment approach with anti-HER2 therapy, through supplementation or switching to another therapy as necessary based on receptor switch.
Read More ›
Efficacy and Safety of First-Line Pertuzumab with Trastuzumab plus an Aromatase Inhibitor in Patients with HER2- and HR-Positive Metastatic or Locally Advanced Breast Cancer
SABCS 2020 – HER2+
The potential role of the combination of pertuzumab, hormone therapy, plus an aromatase inhibitor as first-line treatment for HER2-positive metastatic or locally advanced breast cancer is further supported by the final analysis of the PERTAIN trial.
Read More ›
Evaluating the Impact of Brain Metastases in Real-World Treatment Patterns and Healthcare Resource Utilization Among HER2-Positive Metastatic Breast Cancer Patients
SABCS 2020 – HER2+
Among patients with HER2-positive metastatic breast cancer, the healthcare resource utilization of brain metastases is significantly higher when compared with patients without brain metastases, underscoring the critical need for effective systemic therapies that improve outcomes and decrease the burden of disease.
Read More ›
Treatment Outcomes of Elderly Women with HER2-Positive Advanced Breast Cancer: Real-World Analysis
SABCS 2020 – HER2+
Elderly patients with HER2-positive advanced breast cancer demonstrated shorter chemotherapy durations, poorer overall survival, and increased rates of adverse events, emphasizing the need for prospective studies to improve outcomes.
Read More ›
Treatment Patterns Among Patients with HER2-Positive Metastatic Breast Cancer: Real-World Evidence Study
SABCS 2020 – HER2+
This real-world study of community-based oncology clinics demonstrates that patients receive variable treatment patterns in later line settings, and there is no clear management strategy being utilized. With recently approved targeted therapies for HER2-positive metastatic breast cancer, improvements in patient outcomes are slowly being seen.
Read More ›
A STEPP Analysis of the APHINITY (BIG 4-11) Trial: 6-Year Results
SABCS 2020 – HER2+
Identified subpopulations of patients showed the largest absolute advances in 6-year invasive disease-free survival for pertuzumab compared with placebo.
Read More ›
Treatment-Related Amenorrhea with Trastuzumab Emtansine plus Pertuzumab in the Phase 3 Neoadjuvant KRISTINE Trial
SABCS 2020 – HER2+
Treatment-related amenorrhea with a standard combination chemotherapy regimen occurred at a rate that was nearly double that observed with trastuzumab emtansine plus pertuzumab, implying that gonadal function may be preserved through an antibody–drug conjugate regimen.
Read More ›
Real-World Analysis of Neoadjuvant and Adjuvant Treatment Patterns in HER2-Positive Early Breast Cancer
SABCS 2020 – HER2+
An increase in neoadjuvant therapy use has paralleled shifts in the standard anti-HER2 therapies; however, neoadjuvant patients are primarily treated with dual HER2 blockade and chemotherapy, with a taxane-based regimen preference.
Read More ›
Suitability of Chemotherapy De-escalation Based on Response to Neoadjuvant Paclitaxel + Trastuzumab + Pertuzumab in HER2-Positive Breast Cancer: The DAPHNE Trial
SABCS 2020 – HER2+
De-escalation of adjuvant cytotoxic chemotherapy among patients who experienced pathologic complete response in early-stage HER2-positive breast cancer appears to be an acceptable approach for both patients and physicians.
Read More ›
Evaluation of Venetoclax plus Trastuzumab Emtansine in Patients with Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer
SABCS 2020 – HER2+
Based on the premise that BCL-2 may play a key role in HER2-positive breast cancer, a phase 1b/2, randomized, placebo-controlled trial will evaluate venetoclax plus trastuzumab emtansine.
Read More ›
Page 1 of 2
1
2
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us